Drug-Drug:
- ↑risk of potentially fatal arrhythmias with quinidine, dofetilide, methadone, disopyramide, dronedarone, or pimozide; concurrent use contraindicated.
- ↑risk of excessive sedation with midazolam (PO) or triazolam; concurrent use contraindicated.
- ↑risk of adverse CNS reactions with pimozide; concurrent use contraindicated.
- ↑risk of myopathy with lomitapide, simvastatin, or lovastatin; concurrent use contraindicated.
- ↑risk of vasoconstriction with ergot alkaloids (dihydroergotamine, ergotamine, methylergonovine); concurrent use contraindicated.
- Significantly ↑ avanafil, nisoldipine, felodipine, isavuconazonium, lurasidone, ranolazine, eplerenone, finerenone, voclosporin, and irinotecan levels; concurrent use contraindicated.
- Significantly ↑ colchicine, fesoterodine, and solifenacin levels in patients with varying degrees of hepatic or renal impairment; concurrent use contraindicated.
- Significantly ↑ eliglustat levels in patients who are poor or intermediate CYP2D6 metabolizers or those taking moderate or strong CYP2D6 inhibitors; concurrent use contraindicated.
- ↑risk of bradycardia and heart block with ivabradine; concurrent use contraindicated.
- ↑risk of tumor lysis syndrome with venetoclax during initiation and ramp-up phase of venetoclax in patients with chronic lymphocytic leukemia or small lymphocytic leukemia; concurrent use during these dosing phases contraindicated.
- May also ↑ levels and the risk of toxicity from alprazolam, aripiprazole, atorvastatin, axitinib, bortezomib, budesonide, buspirone, busulfan, carbamazepine, cariprazine, cilostazol, clarithromycin, cobicistat, cyclosporine, dabrafenib, dasatinib, dexamethasone, diazepam, digoxin, docetaxel, elbasvir/grazoprevir, eletriptan, entrectinib, erlotinib, erythromycin, fentanyl, fluticasone, gefitinib, glecaprevir/pibrentasvir, haloperidol, ibrutinib, imatinib, ivacaftor, ixabepilone, lapatinib, lumacaftor/ivacaftor, methylprednisolone, midazolam, mobocertinib, nilotinib, oral hypoglycemic agents, pemigatinib, ponatinib, quetiapine, ramelteon, rifabutin, risperidone, ritonavir, sirolimus, sunitinib, suvorexant, tacrolimus, talazoparib, tenofovir disoproxil fumarate, trabectedin, tretinoin (oral), vinca alkaloids, and warfarin.
- May ↑ levels and the negative inotropic effects of calcium channel blockers.
- Absorption of tablets, 200-mg capsules, and oral solution ↓ by antacids, H2 blockers, sucralfate, proton pump inhibitors, or other agents that increase gastric pH (take
1 hr before or 2 hr after itraconazole). - Antacids, histamine H2 blockers, sucralfate, proton pump inhibitors, or other agents that ↑ gastric pH may ↑ levels of 65-mg capsules; may need to ↓ itraconazole dose.
- Phenytoin, phenobarbital, nevirapine, isoniazid, rifampin, rifabutin, efavirenz, and carbamazepine may ↓ levels and effectiveness; ↑ itraconazole dose.
- If hypokalemia occurs, the risk of digoxin toxicity is ↑.
Drug-Food:
- Food↑ absorption.